Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer

Por Ali, H R, Dawson, S-J, Blows, F M, Provenzano, E, Pharoah, P D, Caldas, C
Publicado em 2012

Prevalent cases in observational studies of cancer survival: do they bias hazard ratio estimates?

Por Azzato, E M, Greenberg, D, Shah, M, Blows, F, Driver, K E, Caporaso, N E, Pharoah, P D P
Publicado em 2009

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer

Por Ali, A M G, Dawson, S-J, Blows, F M, Provenzano, E, Ellis, I O, Baglietto, L, Huntsman, D, Caldas, C, Pharoah, P D
Publicado em 2011

Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival

Por Dawson, S J, Duffy, S W, Blows, F M, Driver, K E, Provenzano, E, LeQuesne, J, Greenberg, D C, Pharoah, P, Caldas, C, Wishart, G C
Publicado em 2009

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape

Por Modelska, A, Turro, E, Russell, R, Beaton, J, Sbarrato, T, Spriggs, K, Miller, J, Gräf, S, Provenzano, E, Blows, F, Pharoah, P, Caldas, C, Le Quesne, J
Publicado no Cell Death Dis (2015)

Astronomical algorithms for automated analysis of tissue protein expression in breast cancer

Por Ali, H R, Irwin, M, Morris, L, Dawson, S-J, Blows, F M, Provenzano, E, Mahler-Araujo, B, Pharoah, P D, Walton, N A, Brenton, J D, Caldas, C
Publicado em 2013

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Por Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Publicado em 2010

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received

Por Dawson, S-J, Makretsov, N, Blows, F M, Driver, K E, Provenzano, E, Le Quesne, J, Baglietto, L, Severi, G, Giles, G G, McLean, C A, Callagy, G, Green, A R, Ellis, I, Gelmon, K, Turashvili, G, Leung, S, Aparicio, S, Huntsman, D, Caldas, C, Pharoah, P
Publicado em 2010

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised...

Por Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R CF, Twelves, C J, Cameron, D, Bartlett, J MS, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J
Publicado em 2012

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

Por Wishart, G C, Bajdik, C D, Dicks, E, Provenzano, E, Schmidt, M K, Sherman, M, Greenberg, D C, Green, A R, Gelmon, K A, Kosma, V-M, Olson, J E, Beckmann, M W, Winqvist, R, Cross, S S, Severi, G, Huntsman, D, Pylkäs, K, Ellis, I, Nielsen, T O, Giles, G, Blomqvist, C, Fasching, P A, Couch, F J, Rakha, E, Foulkes, W D, Blows, F M, Bégin, L R, van't Veer, L J, Southey, M, Nevanlinna, H, Mannermaa, A, Cox, A, Cheang, M, Baglietto, L, Caldas, C, Garcia-Closas, M, Pharoah, P D P
Publicado em 2012